Meeting
2014 Genitourinary Cancers Symposium
Multicenter sequential phase II study of flavopiridol plus oxaliplatin (alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR).
Authors
Darren Richard Feldman
Memorial Sloan-Kettering Cancer Center, New York, NY
Darren Richard Feldman , Walter Michael Stadler , Leonard Joseph Appleman , David I. Quinn , Brian Addis Costello , Gary K. Schwartz , Victor E. Reuter , Kaitlyn Woo , Sujata Patil , Anne Fusco , Sloane C. Smith , Jeremie Carlson , George J. Bosl , Robert John Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Penile, Urethral, and Testicular Cancers
Clinical Trial Registration Number
NCT00957905
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 364)
DOI
10.1200/jco.2014.32.4_suppl.364
Abstract #
364
Poster Bd #
C7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).
First Author: Choong-kun Lee
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.
First Author: Derek B. Grose
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma.
First Author: Jonathan Matthew Hernandez
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
First Author: Yongkang Xu